Thorough QT StudiesQuestions and Quandaries

被引:0
|
作者
Marek Malik
Christine E. Garnett
Joanne Zhang
机构
[1] St George’s,Division of Cardiac and Vascular Sciences
[2] University of London,Pharmacometrics Staff, Office of Clinical Pharmacology, Center of Drug Evaluation and Research
[3] Food and Drug Administration,Division of Biometrics VI, Office of Biostatistics/Office of Translational Sciences, Center of Drug Evaluation and Research
[4] Food and Drug Administration,undefined
来源
Drug Safety | 2010年 / 33卷
关键词
Moxifloxacin; Class Comparator; Outlier Analysis; Supratherapeutic Dose; Proarrhythmic Risk;
D O I
暂无
中图分类号
学科分类号
摘要
The International Conference on Harmonisation E14 Guidance was successful in largely standardizing the conduct of the so-called thorough QT/QTc studies (TQTS). Nevertheless, there is still a spectrum of frequently encountered problems with details of design, conduct and interpretation of TQTS. Several of these challenges are reviewed here, starting with explaining that the TQTS goal is only to identify drugs for which the proarrhythmic risk might be considered excluded for the purposes of regulatory benefit-risk assessment. Suggestions are made on how to categorize and quantify or exclude proarrhythmic risk if the TQTS is positive. There is a conceptual need for TQTS, and this is discussed, together with reasons why restricted clinical registries cannot prove the absence of proarrhythmic liability of any drug.
引用
收藏
页码:1 / 14
页数:13
相关论文
共 50 条
  • [31] Levetiracetam thorough QT study: lack of proarrhythmic effect
    Hulhoven, R.
    Rosillon, D.
    Bridson, W.
    Salas, E.
    Chen, D.
    Watanabe, S.
    Meesus, M.
    Stockis, A.
    EPILEPSIA, 2007, 48 : 64 - 65
  • [32] Brivaracetam thorough QT study: Lack of proarrhythmic effect
    Rosillon, D.
    Astruc, B.
    Bendahmane, S.
    Hulhoven, R.
    Meeus, M. A.
    Troenaru, M.
    Watanabe, S.
    Stockis, A.
    EPILEPSIA, 2007, 48 : 329 - 329
  • [33] Thorough QT study with recommended and supratherapeutic doses of tolterodine
    Olshansky, B.
    Serra, D. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 231 - 232
  • [34] Lessons Learned From Hundreds of Thorough QT Studies
    Zhang, Joanne
    Chen, Huifang
    Tsong, Yi
    Stockbridge, Norman
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (03) : 392 - 397
  • [35] Levetiracetam thorough QT study: Lack of proarrhythmic effect
    Hulhoven, Reginald
    Rosillon, D.
    Bridson, W.
    Salas, E.
    Chen, D.
    Watanabe, S.
    Meeus, M. A.
    Stockis, A.
    EPILEPSIA, 2007, 48 : 361 - 361
  • [36] Electrocardiographic Data Quality in Thorough QT/QTc Studies
    Lars Johannesen
    Christine Garnett
    Marek Malik
    Drug Safety, 2014, 37 : 191 - 197
  • [37] A Thorough QT/QTc Study of Clobazam in Healthy Volunteers
    Tolbert, Dwain
    Gordon, Judy
    Harris, Stuart
    Walzer, Mark
    Bekersky, Ihor
    Reid, Susan
    CLINICAL THERAPEUTICS, 2017, 39 (10) : 2073 - 2086
  • [38] Limb Lead Interchange in Thorough QT/QTc Studies
    Salvi, Vaibhav
    Karnad, Dilip R.
    Panicker, Gopi Krishna
    Kothari, Snehal
    Hingorani, Pooja
    Natekar, Mili
    Mahajan, Vaibhav
    Narula, Dhiraj
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (10): : 1468 - 1473
  • [39] Thorough QT Studies and Indirect Causes of QTc Changes
    Malik, Marek
    Stockbridge, Norman
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2012, 35 (12): : 1411 - 1412
  • [40] Validation testing in thorough QT/QTc clinical trials
    Tsong, Yi
    Zhong, Jinglin
    Chen, Wen Jen
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (03) : 529 - 541